Glenmark Pharmaceuticals has just received approval from the Drugs Controller General of India (DCGI) to launch the oncology drug BRUKINSA in India. This is a big deal because BRUKINSA, also known as zanubrutinib, offers a new treatment option for people fighting blood cancers.
BRUKINSA will be available under this brand name and is developed by BeiGene, now BeOne Medicines—a global leader in cancer treatments.
It is the first and only Bruton’s tyrosine kinase (BTK) inhibitor approved in India to treat five types of B-cell blood cancers: chronic lymphocytic leukemia (CLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and follicular lymphoma (FL).
So, what does this mean for the average person? India faces a huge burden from blood cancers. Roughly every five minutes, a new blood cancer case is diagnosed, and sadly, about 70,000 people die from these diseases each year. The arrival of BRUKINSA gives hope with its proven ability to control these tough cancers and improve patients’ quality of life.
BRUKINSA stands out because it has shown strong results in clinical trials worldwide. Studies like ALPINE, ASPEN, and SEQUOIA back its effectiveness and safety.
Also Read $175M Investment Lights Up Felix Pharmaceuticals’ Mission to Save Pets Worldwide
For example, the ALPINE study showed BRUKINSA caused fewer serious heart problems compared to ibrutinib, another BTK inhibitor. This is important because side effects often make patients stop their treatment. BRUKINSA’s flexible dosing, either once or twice daily, helps doctors personalize care based on what the patient needs.
Let’s be honest—blood cancer isn’t an easy fight. Treatments can be harsh, and side effects can feel like a bad side quest in a video game you didn’t sign up for.
But BRUKINSA is like that rare power-up, offering a smoother ride and fewer unexpected battles, according to the clinical data.
For anyone affected by these blood cancers, Glenmark’s launch of BRUKINSA could be a game changer. This drug brings new options at a crucial time when India needs better, safer cancer therapies.
Also Read Say Goodbye to Cancer Risk with These 10 Easy, Life-Changing Habits!
